In this paper we propose network methodology to infer prognostic cancer biomarkers, based on the epigenetic pattern DNA methylation. Epigenetic processes such as DNA methylation reflect environmental risk factors, and are increasingly recognised for their fundamental role in diseases such as cancer. DNA methylation is a gene-regulatory pattern, and hence provides a means by which to assess genomic regulatory interactions. Network models are a natural way to represent and analyse groups of such interactions. The utility of network models also increases as the quantity of data and number of variables increase, making them increasingly relevant to large-scale genomic studies. We propose methodology to infer prognostic genomic networks from a DNA methylation-based measure of genomic interaction and association. We then show how to identify prognostic biomarkers from such networks, which we term 'network community oncomarkers'. We illustrate the power of our proposed methodology in the context of a large publicly available breast cancer data-set.
Introduction
Complex systems which can be modelled as networks are ubiquitous. Well-known examples include social/communication networks [Beguerisse-Díaz et al., 2014] and economic networks [Saavedra et al., 2014] , as well as many others in the biological sciences such as ecological networks [Nandi et al., 2014] , gene networks Pan, 2010, Li and , protein networks [Mardia, 2013, Tran and Kwon, 2013] , and metabolic networks [Reznik et al., 2013] . Over the past few years in cell biology, much focus has shifted from investigation of individual genes, to pathways of genes, to gene networks. The interest in novel methodology for network analysis in cell biology follows from the recognition that examining the way genes work in groups often yields more accurate inference of biological processes. Further, by considering groups of genes together, a level of statistical significance can be obtained which is not possible when genes are considered individually [Jacob et al., 2012] .
Epigenetic patterns are gene-regulatory patterns, meaning that they influence the activity of particular genes, among other phenomena [Jones, 2012] . Epigenetic information can be modulated during the lifetime of an organism by environmental cues [Feinberg et al., 2006 , Cooney, 2007 , Christensen et al., 2009 . As such, epigenetics can be considered to be an interface between the genome and the environment, and consequently also a conduit for environmental risk factors. Alterations in the epigenetic pattern DNA methylation are among the earliest changes in human carcinogenesis [Feinberg et al., 2006] , and hence DNA methylation patterns are expected to yield important prognostic information useful for biomarker development. DNA methylation patterns are thought promising for biomarker development in a wide variety of physiological systems and organs [Verschuur-Maes et al., 2012 , Van Hoesel et al., 2013 , Fleischer et al., 2014 , Kishida et al., 2012 , Gao et al., 2013 , Kang et al., 2001 , 2003 , Bhagat et al., 2012 , Yamamoto et al., 2012 , Luo et al., 2014 , Navarro et al., 2012 , Maekawa et al., 2013 .
It is well established that DNA methylation plays an important role in gene regulation, and hence DNA methylation patterns often reflect gene regulatory behaviour [Jones, 2012] . Changes in DNA methylation are highly stochastic. The time-scale over which these changes take place is much faster than DNA mutations can arise, but much slower than the transient and periodically varying activity of individual genes, and this time-scale is ideal for biomarker development. DNA methylation data are extremely noisy; however, statistics which summarise DNA methylation patterns at the gene level have been shown to have much utility as analytical tools [Bartlett et al., 2013] . It has been shown previously
Proposed methodology
An overview of our proposed methodology appears in figure 1, following which the component parts of this methodology are described in detail.
(1) Calculate the DNAm network interaction measure for each pair of genes, and for each patient (2) Calculate a Wald statistic (adjusted for clinical covariates) as a measure of prognostic ability for each pair of genes, across all patients (3) Infer the prognostic network, by fitting a mixture model to identify significantly non-zero Wald statistics, defining these prognostic interactions as network edges (4) Detect network community oncomarkers as groups of genes among which there is a high density of prognostic interactions / network edges (5) Summarise the DNA methylation network interaction measures over the prognostic interactions / network edges of each network community oncomarker, to give a one-number prognostic score for each patient, and for each network community oncomarker 
DNA Methylation Network Interaction Measure
DNA methylation is a chemical modification to DNA which may occur at numerous locations within a gene: the pattern of these modifications within a gene forms a 'DNA methylation profile'. Using canonical correlation analysis (CCA) [Hotelling, 1936] we previously proposed a statistic [Bartlett et al., 2014] which measures the strength of interaction or association between a pair of genes (network nodes) in a single sample/patient, based on DNA methylation profiles (figure 2). This statistic quantifies the extent to which the DNA methylation profiles of a pair of genes explain each other. It is based only on measurements of the DNA methylation profiles of that pair of genes, and it acts as a surrogate for a measure of the extent to which this pair of genes behave interactively or associatively. Such behaviour may include transcriptional regulation or co-regulation, or other types of biochemical interaction, influencing gene expression levels, isoforms and the presence of alternatively spliced gene products, among other phenomena [Jones, 2012] . The details of this DNA methylation network interaction measure are as follows. The DNA methylation network interaction measure is defined by analogy to CCA. CCA aims to discover linear combinations of variables of one type, and linear combinations of variables of another type, so that these combinations best explain each other. In this context, a particular way of combining (by scaling and adding) the deviations from the mean methylation profile at a number of locations within one gene might be particularly effective at explaining a particular combination of (again, by scaling and adding) the deviations from the mean methylation profile at a number of locations in another gene, and vice-versa. There will probably be fewer ways in which the methylation levels of these genes covary across the samples than there are locations at which methylation is measured along the genes; this is because the methylation level is highly correlated at many locations along a particular gene. CCA finds the most important components of this covariation across samples.
CCA seeks to find the vectors a and b, in the p and q dimensional spaces of variables X = (x 1 , x 2 , ..., x p ) and Y = (y 1 , y 2 , ..., y q ) respectively, which maximise the correlation ρ = cor (a X, b Y) defined accord-ing to equation 1:
where
are the covariance matrices of X and Y respectively,
is the cross-covariance matrix of X and Y, and µ X and µ Y are the mean vectors of X and Y.
Two genes X and Y have corresponding methylation profiles which are measured for sample / patient k at p and q CpGs (loci) respectively along these genes. Denoting these measurements by the variables x 1 , ...x p and y 1 , ..., y q for genes X and Y respectively, the DNA methylation profiles for these genes, for patient k, can be represented by the vectors x(k) and y(k), which have p and q entries respectively. A measure of DNA methylation network interaction ρ XY (k), of the methylation profiles of genes X and Y for sample k, can then be defined by analogy with equation 1, according to equation 2:
XY are estimated from healthy rather than cancer samples in the methylation data set, according to equations 3 -5,
and n h is the number of healthy samples in the data set. When the DNA methylation network interaction measure ρ XY (k) is large (i.e., close to 1), the corresponding pair of genes explain each others' generegulatory behaviour (as reflected in their methylation profiles) well, or have otherwise well-correlated interactive or associative behaviour, for sample/patient k. Hence, ρ XY (k) measures (according to their DNA methylation profiles) the level of interaction or association between genes X and Y in tumour sample k, compared to typical interactions between these genes in healthy tissue. The DNA methylation network interaction measure. A combination of the variation of the healthy methylation profiles in regions (a) and (b) of gene X explains well / is well-explained by a combination of the variation of the healthy methylation profiles in regions (c) and (d) of gene Y. The green cancer sample varies by a large amount about the mean methylation profile and in a typical way in these regions in both genes. Hence, the green sample corresponds to a high level of network interaction for this sample, ρXY = 1. The equivalent variations in the other regions of these genes do not explain each other well, and so the red sample, which varies by a large amount in these other regions and varies less and in an atypical way in regions (a) -(d), corresponds to a low level of network interaction, ρXY = 0.07. Genes X and Y are likely to have different numbers of methylation measurement locations (i.e., variables X and Y are of different dimension). The ordering of the measurement locations has no influence on the calculation of ρ, as long as the ordering is consistent across samples.
Prognostic Network Construction
Our proposed methodology for inference of network oncomarkers is based on a prognostic interaction network over m genes. This network is represented by the m × m adjacency matrix A, in which an edge is defined to to be present (i.e., A ij = 1) if and only if the corresponding pair of genes (nodes) are prognostic according to the DNA methylation network interaction measure of section 2.1. Otherwise, we set A ij = 0. N.B., i and j are now redefined compared to the last section, so that they index genes rather than DNA methylation locations. This formulation will not be problematic, because all subsequent analysis is carried out at the level of genes rather than DNA methylation locations. To identify prognostic edges, we use the Cox proportional hazards model [Cox, 1972] to calculate a Wald-statistic z ij for each of the m 2 pairs of genes in the network. The Wald statistic quantifies the strength of association of the DNA methylation network interaction measure ρ ij for the pair of genes i and j (i = 1, ..., m and j = 1, ..., m) with patient survival outcome across patients k (k = 1, ...n). We use a multivariate Cox model, adjusting these Wald statistics for clinical covariates. We adjust in this way in order to detect novel DNA methylation biomarkers which are independent of known prognostic clinical features.
The Wald statistic is asymptotically normally distributed with unit variance [Harrell, 2001] , and we can therefore model the distribution of our observed Wald statistics, z ij , as a mixture of Gaussians. We have previously demonstrated the utility of mixture modelling to a related network inference problem [Bartlett, 2015] , and a similar approach can be applied in this context. We model the z ij as a Gaussian mixture as follows:
where N µ ij , σ 2 is the normal distribution. We fit this mixture model to each observed statistic z ij , and then infer whether, given z ij , it is more likely that µ ij = 0, or µ ij = 0, leading to the estimateŝ A ij = 0 orÂ ij = 1 respectively. We fit this model using the empirical Bayes procedure [Johnstone and Silverman, 2004] , defining a mixture prior distribution f prior (µ ij ) over the µ ij of equation 6:
where w is the mixing parameter between the two components, which can also be interpreted as w = E [p (A ij = 1)], and γ (·|a) is the Laplace probability density function,
where we use the standard value of a = 0.5 [Johnstone and Silverman, 2004] . Taking the mixture components to have Gaussian likelihoods, f N · µ ij , σ 2 , as in equation 6, it follows from equation 7 that the posterior density over the observed prognostic Wald statistic z ij is:
where the marginal density is:
where g (µ ij ) is the convolution of the Laplace density with the standard normal density. If the Laplace distribution in the prior (equation 7) were replaced with a Gaussian, then the marginal distribution (equation 9) would be a mixture of Gaussians. However, as noted previously [Johnstone and Silverman, 2004] , this empirical Bayes procedure requires a prior with tails that are exponential or heavier. Hence, we similarly use the Laplace rather than Gaussian prior which is a slight model mis-specification. Although a separate model is fitted to each observed Wald statistic z ij , a common weight w i is used for each gene/node i. This estimate of w i is found as the value which maximises the marginal likelihood (equation 10) of the observed statistics z ij over all the pairwise comparisons of i with j, j = i. This allows the model for each such pairwise comparison (i, j) to 'borrow strength' from all the other comparisons (i, j ), j = i, j = j:ŵ
For a particular gene i, if the z ij are mostly close to zero, then w i will be set low, which means that fewer edges (A ij = 1) will be detected; this hence corresponds to i being a low-degree node. If for a different gene i the z ij are generally further from zero, thenŵ i will be set high, which corresponds more edges being detected; this hence corresponds to i being a high-degree node. Therefore, settingŵ i separately for each gene i allows adaptation to a heterogenous degree distribution in A. As previously [Johnstone and Silverman, 2004] , we use the posterior median to obtain the estimateμ ij . Then we make a conservative estimate of A as follows:
A ij =0 otherwise.
Community and Oncomarker Detection
Network nodes can be grouped together according to their propensity to interact with each other, for example groups of friends in a social network, or functional subnetwork modules in a biological network; this method is referred to as community detection Newman, 2002, Newman, 2004] . We use community detection to naturally infer groups of genes in our constructed prognostic network. These groups of genes interact differently in cancer than in healthy tissue, in a way which is predictive of how advanced the disease is. We term these groups 'network community oncomarkers'. Within a network community oncomarker the genes may interact with each other more (relative to healthy tissue) the more serious the disease is (as in figure 6c ), or they may interact with each other less the more serious the disease is, (as in figure 6a ). We carry out the task of community detection by fitting the degree-corrected stochastic blockmodel [Holland et al., 1983, Bickel and Chen, 2009] . We fit this model in an efficient way by regularised spectral clustering [Qin and Rohe, 2013] , calculating the optimum number of communities to divide the network into by the network histogram method [Olhede and Wolfe, 2014] . Each community identified in this way represents a potential network community oncomarker. For each network community oncomarker, we then calculate a prognostic score for each patient, by summarising the DNA methylation network interaction measure over this group of genes. This prognostic score can be used as a one-number summary of disease prognosis for that patient according to that network community oncomarker. The following points are important when calculating these summaries. Some gene-gene interactions will correspond to an increasingly negative DNA methylation network interaction measure ρ ij for worse patient prognosis. On the other hand, some gene-gene interactions will correspond to an increasingly positive ρ ij for worse prognosis. This means that care must be taken when summarising the network interaction measure across the network community oncomarker. Also, for the same amount of prognostic information conveyed, the magnitude of the changes in the network interaction measure may not be the same for each prognostic pairs of genes. To address these points, we combine the ρ ij across the prognostic pairs of genes of the network community after first multiplying them by the corresponding fitted Cox proportional hazards model coefficientsθ ij , obtained as described at the start of section 2.2. Under the Cox proportional hazards model, the fitted model coefficientθ ij for a predictor ij gives the log of the hazard-ratio (HR) for that predictor in the model, i.e., log (HR ij ) =θ ij . The hazard ratio is the scale-factor increase in probability of an event (e.g., death) occurring per unit time, relative to the baseline hazard (e.g., compared to a control group). Hence, these coefficients are interpretable in the same way, without scaling issues, across fitted models. This means that, for patient k, we can combine the DNA methylation network interaction measures over a network community oncomarker to generate a one-number prognostic score, as follows:
where C is the set of nodes in the network community oncomarker,Â is the inferred adjacency matrix, ρ ij (k) is the DNA methylation network interaction measure for genes/nodes i and j and patient k, andθ ij is the corresponding fitted Cox multivariate proportional-hazards model coefficient. Network edges/DNA methylation network interaction measures ρ ij which increase with poor prognosis (i.e., pairs of genes which interact more as the disease progresses, coloured green in figure 6), will correspond tô θ ij > 0. Hence, an increase in such a ρ ij will increase the prognostic score. Equivalently, network edges/DNA methylation network interaction measures ρ ij which decrease with poor prognosis (i.e., pairs of genes which interact less as the disease progresses, coloured red in figure 6), will correspond toθ ij < 0. Hence, a decrease in such a ρ ij will also increase the prognostic score.
An equivalent gene-expression interaction measure
To examine further the hypothesis that the DNA methylation network interaction measure is a reflection of co-regulatory or co-regulated gene-expression patterns (among other genomic effects), we need an equivalent measure of gene-gene interaction or association in terms of gene expression. We can calculate such a measure, ρ expr XY (k), for gene expression measurements x expr (k) and y expr (k) for the genes X and Y and patient k, as follows (equation 12):
whereμ (h)
and σ
The intuition of equation 12 is that when the gene expression measurements x expr (k) and y expr (k) deviate in the same sample from the corresponding healthy mean expression levels, this measure will be nonzero. When this occurs in the same samples as the DNA methylation network interaction measure ρ XY (k) is also non-zero, we will see a correlation between ρ XY (k) and ρ expr XY . These interaction measures for methylation and expression, ρ XY (k) and ρ expr XY , are equivalent because they both measure deviation from typical interactive behaviour in healthy/control samples. We note that, that while ρ expr XY works satisfactorily for this comparison, it would not be expected to be a sensitive statistic to use as a prognostic tool.
Examples
We present an example application of the methodology proposed in section 2 to a large publicly available breast cancer invasive carcinoma (BRCA) data-set downloaded from the Cancer Genome Atlas (TCGA). We downloaded an initial batch of DNA methylation data for tumour samples taken from 175 individuals (the training set), together with clinical data for these samples relating to patient survival outcome, and the covariates age, disease stage, and residual disease. These training data were used to detect potential network community oncomarkers. We then downloaded DNA methylation data for a further 528 tumour samples (the test set), together with data for the same clinical features: these independent samples were used to validate the potential network community oncomarkers. We also downloaded corresponding DNA methylation data for healthy breast tissue samples from 98 individuals to form a reference population of DNA methylation profiles for this analyisis, and we downloaded gene expression data for 216 of the tumours for which DNA methylation data were also available.
We inferred the binary prognostic adjacency matrix A for the 175 samples of the BRCA training data set according to the methods set out in sections 2.1 -2.2. DNA methylation data were available for 14829 genes, and hence the number of nodes/genes m in the inferred adjacency matrixÂ is m = 14829. The presence of an edge inÂ, i.e.Â ij = 1, indicates that the interaction between genes i and j is associated with disease progression. The edge density ofÂ is 0.0035, i.e. p(Â ij = 1) = 0.0035. We then extracted the connected component from this inferred network and carried out community detection on this connected component as described in section 2.3. This resulted in 33 communities ranging from 116 to 285 nodes in size. The reduced adjacency matrix relating to these communities (with m = 5668 and p(Â ij = 1) = 0.023) is shown in figure 3 .
Figure 3: The inferred prognostic adjacency matrix after community detection. Entries in the adjacency matrix equal to 1 (representing a network edge) are coloured blue. Detected communities are outlined in black. The potential network community oncomarkers which are analysed further in figures 4 -7 and tables 1 -2 and S1 -S5 are outlined in red, and labelled (a) -(e). We validated each of the 33 potential network community oncomarkers in the 528 independent tumour samples of the test/validation set. We note that these 528 samples were not used in any way to identify the 33 potential network community oncomarkers shown in figure 3. Hence in this validation each of these 528 patients were classified individually according to prognosis without reference to the other validation samples. This means that comparing these prognostic classifications assigned to the validation samples is a true test of prognostic ability of the network community oncomarkers. To carry out the validation, we calculated the prognostic score for the 528 independent/unseen samples of the test set, based on the inferred prognostic adjacency matrixÂ and the fitted Cox multivariate proportional hazards model coefficientsθ obtained from the initial 175 samples of the training set. Using this trained model, we calculated one prognostic score for each potential network community oncomarker for each of the 528 unseen test-set samples. We then tested the prognostic score, for each potential network community oncomarker, for significant prediction of patient survival outcome in these 528 unseen test-set samples. The five potential network community oncomarkers which validated in this way with the highest level of significance are outlined in red in figure 3 . Figure 6 shows the five network community oncomarkers which validated most significantly. Green edges indicate gene-gene interactions which become stronger with disease progression. Red edges indicate interactions which become weaker with disease progression. Hence, the network community oncomarkers of figures 6a and figure 6b can be considered to be functional subnetwork modules which becomes less active as the cancer progresses (comprised of 99% and 96% red edges, respectively). On the other hand, figure 6c and 6d can be considered to be functional subnetwork modules which becomes more active as the cancer progresses (both comprised of 99% green edges). Then the network community oncomarker of figure 6e contains a mixture of these effects (comprised of 87% red and 13% green edges). However, each of these network community oncomarkers represents a functional subnetwork module which is rewired in a way which is advantageous for the cancer, in favour of proliferation, and against cell death and immune function. The genes/nodes of these network community oncomarkers are shown in tables S1 -S5; they list many genes related to cell proliferation (e.g., CDKL1, NKAPL, MAPK6), developmental processes (e.g. , HOXD10, HOXB9, HOXC10, HOXA13, HOXC12, HOXD13) , and immune function (e.g., VSIG2, IL36B, RBPJ). We hypothesise that the DNA methylation network interaction measure is a reflection of co-regulatory or co-regulated gene-expression patterns, among other genomic effects. We tested this hypothesis by comparing the DNA methylation network interaction measure ρ XY for a pair of genes XY (equation 2) with an equivalent measure of interactive behaviour of these genes in terms of their expression levels, ρ expr XY (equation 12). Correlation test p-values for the comparison between ρ XY and ρ expr XY appear in figure 7. It is clear that in these histograms, there is a concentration of significant p-values close to zero, indicating a departure from the null hypothesis uniform distribution, and demonstrating an association between ρ XY and ρ expr XY for many of the edges/interactions of each network community oncomarker. However, there are also many non-significant p-values visible in these histograms, indicating that there are other genomic interactive effects present which cannot be explained in terms of gene expression (as assessed by mRNA levels) alone. Such effects are expected to include the influence of alternatively spliced products or isoforms [Jones, 2012] and the interaction between non-coding transcripts and the epigenome [Lai and Shiekhattar, 2014] .
Discussion
In this paper, we have proposed methodology to detect cancer biomarkers based on the epigenomic pattern DNA methylation. This methodology builds on a measure of pairwise interaction between genes, based on the epigenomic gene-regulatory pattern DNA methylation. Based on this measure, the methodology we have introduced in this paper allows inference of prognostic genomic networks, and identification of prognostic biomarkers from such networks using community detection methodology. We call these 'network community oncomarkers'; they are groups of nodes/genes among which there is a high density of prognostic genomic interactive or associative behaviour. We have demonstrated that within these communities, the DNA methylation network interaction measure is highly associated with co-regulatory behaviour linked to gene expression (at the mRNA level), giving functional relevance to the findings. However, there are also likely to be a range of genomic interactive effects present which are measured by the DNA methylation network interaction measure but which are not reflected in mRNA levels. Our proposed methodology also allows a one-number prognostic score for a network community oncomarker to be calculated for each patient/sample: this prognostic score is a measure of disease progression in that patient.
Our proposed methodology uses mixture modelling to infer network structure from prognostic association between genes, and draws on practical approaches to community detection to obtain oncomarkers from this prognostic network. Mixture modelling has previously been shown to be an effective approach to the related problem of clustering in networks [Vu et al., 2013] . This suggests that more general methodology could be developed here, in which network and community inference are both carried out simultaneously by model fitting. Network inference has also been carried out previously using multiple node attributes in cell biological data [Katenka et al., 2012] , and those findings could be used as a basis upon which data from other genomic sources could be integrated into the methodology proposed here. Genes also frequently carry out multiple roles in different biological contexts and hence may be involved in more than one functional subnetwork module within a genomic network. Work has been carried out on overlapping stochastic blockmodels [Latouche et al., 2011] , and hence this would be a natural context in which to develop an application for such methodology.
The field of epigenomics is progressing fast and promises many new insights in the near future into unexplained or undiscovered genomic phenomena, for example relating to the so-called 'dark matter' of the genome [Venters and Pugh, 2013] . Epigenomics is also expected to provide new understanding of the mechanisms of disease progression. The discovery that some genomic loci gain or lose methylation in ways which may be unique to cancer suggests that understanding changes in DNA methylation machinery may be essential to understanding oncogenesis [Xie et al., 2013] . The field of network science is also advancing rapidly. Networks are an efficient way to represent and analyse large numbers of variables, which is particularly relevant in modern, large-scale genomic studies. Networks of interactions are a natural way to represent and analyse genomic interactions, associations and processes. Therefore, the study of genomic and epigenomic networks promises to be productive over the coming years for the fields of biology, medicine, statistics. 
Data-sets
DNA methylation (DNAm) data from breast cancer invasive carcinoma (BRCA) tumour samples, collected via the Illumina Infinium HumanMethylation450 platform, were downloaded from The Cancer Genome Atlas (TCGA) project [Hampton, 2006 , Bonetta, 2006 , Collins and Barker, 2007 at level 3. These data were pre-processed by first removing probes with non-unique mappings and which map to SNPs (as identified in the TCGA level 3 data); probes mapping to sex chromosomes were also removed; in total 98384 probes were removed in this way from all data sets. After removal of these probes, 270985 probes with known gene annotations remained. Probes were then removed if they had less than 95% coverage across samples; probe values were also replaced if they had corresponding detection p-value greater than 5%, by KNN (k nearest neighbour) imputation (k = 5). The loci of analysed CpGs were mapped to genes based on annotation information for the Illumina Infinium platform obtained from the R / Bioconductor package 'IlluminaHumanMethylation450k'. The data were also checked for batch effects by hierarchical clustering and correlation of the significant principle components with phenotype and batch: no significant batch effects (which would warrant further correction) were found. We downloaded DNA methylation data for tumour samples from 175 samples/individuals, from TCGA in July 2013, with clinical data available for patient survival outcome, and the clinical covariates age, disease stage, and residual disease. At the same time, we also downloaded corresponding DNA methylation data for healthy tissue for 98 individuals. These data were used to detect potential network community oncomarkers. We then downloaded DNA methylation data for a further 528 tumour samples from TCGA in September 2014, with data for the same clinical features available. These independent samples were used to validate the potential network community oncomarkers. At this time we also downloaded gene expression data from TCGA at level 3, for 216 of the tumours for which we also obtained DNA methylation data. 
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